The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Chemotherapy of leishmaniasis: present challenges
Open accessAbstract
SUMMARY: Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases of our time, affecting millions of people worldwide. The treatment of these serious diseases rely on a few chemotherapeutic agents, most of which are of parenteral use and induce severe side-effects. Furthermore, rates of treatment failure are high and have been linked to drug resistance in some areas. Here, we reviewed data on current chemotherapy practice in leishmaniasis. Drug resistance and mechanisms of resistance are described as well as the prospects for applying drug combinations for leishmaniasis chemotherapy. It is clear that efforts for discovering new drugs applicable to leishmaniasis chemotherapy are essential. The main aspects on the various steps of drug discovery in the field are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M. D., & the WHO Leishmaniasis Control Team (2012) · PLoS ONE · doi:10.1371/journal.pone.0035671 · Cited by 5,141
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Injectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Molecular Aspects of Parasite-Vector and Vector-Host Interactions in Leishmaniasis
Sacks, D., & Kamhawi, S. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.453 · Cited by 432
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Khare, S., Nagle, A. S., Biggart, A., Lai, Y. H., Liang, F., Davis, L. C., Barnes, S. W., Mathison, C. J. N., Myburgh, E., Gao, M.-Y., et al. (2016) · Nature · doi:10.1038/nature19339 · Cited by 407
Späth, G. F., & Beverley, S. M. (2001) · Experimental Parasitology · doi:10.1006/expr.2001.4656 · Cited by 376
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Combination therapy for visceral leishmaniasis
van Griensven, J., Balasegaram, M., Meheus, F., Alvar, J., Lynen, L., & Boelaert, M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70011-6 · Cited by 336
Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-11 · Cited by 324
Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P. C., Beijnen, J. H., Vanaerschot, M., Decuypere, S., Dhakal, S. S., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit102 · Cited by 319
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future
Bray, P. G., Barrett, M. P., Ward, S. A., & de Koning, H. P. (2003) · Trends in Parasitology · doi:10.1016/s1471-4922(03)00069-2 · Cited by 261
Peña, I., Pilar Manzano, M., Cantizani, J., Kessler, A., Alonso-Padilla, J., Bardera, A. I., Alvarez, E., Colmenarejo, G., Cotillo, I., Roquero, I., et al. (2015) · Scientific Reports · doi:10.1038/srep08771 · Cited by 260
Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation
da Silva, R., & Sacks, D. L. (1987) · Infection and Immunity · doi:10.1128/iai.55.11.2802-2806.1987 · Cited by 247
The Leishmania ATP-binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase
Légaré, D., Richard, D., Mukhopadhyay, R., Stierhof, Y.-D., Rosen, B. P., Haimeur, A., Papadopoulou, B., & Ouellette, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102351200 · Cited by 242
Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania.
Mukhopadhyay, R., Dey, S., Xu, N., Gage, D., Lightbody, J., Ouellette, M., & Rosen, B. P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10383 · Cited by 238
Olliaro, P., Guerin, P. J., Gerstl, S., Haaskjold, A. A., Røttingen, J., & Sundar, S. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70296-6 · Cited by 230
Kremsner, P. G., & Krishna, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16680-4 · Cited by 226
War and Infectious Diseases: Challenges of the Syrian Civil War
Sharara, S. L., & Kanj, S. S. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004438 · Cited by 211
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
PEREZVICTORIA, F., SANCHEZCANETE, M., SEIFERT, K., CROFT, S., SUNDAR, S., CASTANYS, S., & GAMARRO, F. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.04.001 · Cited by 211
Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209
Interventions for American cutaneous and mucocutaneous leishmaniasis
González, U., Pinart, M., Rengifo-Pardo, M., Macaya, A., Alvar, J., & Tweed, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004834.pub2 · Cited by 204
Antileishmanial Activity of the Terpene Nerolidol
Arruda, D. C., D'Alexandri, F. L., Katzin, A. M., & Uliana, S. R. B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1679-1687.2005 · Cited by 204
Self-citationInterventions for Old World cutaneous leishmaniasis
Heras-Mosteiro, J., Monge-Maillo, B., Pinart, M., Lopez Pereira, P., Reveiz, L., Garcia-Carrasco, E., Campuzano Cuadrado, P., Royuela, A., Mendez Roman, I., & López-Vélez, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005067.pub5 · Cited by 196
Basselin, M., Denise, H., Coombs, G. H., & Barrett, M. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3731-3738.2002 · Cited by 195
Grondin, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.3057 · Cited by 188
The chemotherapy of tuberculosis: past, present and future [State of the art]
Mitchison, D., & Davies, G. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0083 · Cited by 185
Collin, S., Davidson, R., Ritmeijer, K., Keus, K., Melaku, Y., Kipngetich, S., & Davies, C. (2004) · Clinical Infectious Diseases · doi:10.1086/381203 · Cited by 180
DON, R., & IOSET, J.-R. (2014) · Parasitology · doi:10.1017/s003118201300142x · Cited by 180
Szoka, F. C., Milholland, D., & Barza, M. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.3.421 · Cited by 177
Nabors, G. S., Afonso, L. C., Farrell, J. P., & Scott, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3142 · Cited by 176
Tuberculosis drug discovery in the post‐post‐genomic era
Lechartier, B., Rybniker, J., Zumla, A., & Cole, S. T. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201201772 · Cited by 176
Chunge, C. N., Owate, J., Pamba, H. O., & Donno, L. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90263-e · Cited by 175
The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis
Wyllie, S., Patterson, S., Stojanovski, L., Simeons, F. R. C., Norval, S., Kime, R., Read, K. D., & Fairlamb, A. H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003326 · Cited by 172
Karimkhani, C., Wanga, V., Coffeng, L. E., Naghavi, P., Dellavalle, R. P., & Naghavi, M. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00003-7 · Cited by 172
Interventions for Old World cutaneous leishmaniasis
González, U., Pinart, M., Reveiz, L., & Alvar, J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005067.pub3 · Cited by 170
Miltefosine Affects Lipid Metabolism in Leishmania donovani Promastigotes
Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., & Loiseau, P. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01123-06 · Cited by 163
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
Aguirre, J. P. B., & Hamid, A. M. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010481.pub2 · Cited by 162
Zhou, Y., Messier, N., Ouellette, M., Rosen, B. P., & Mukhopadhyay, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404383200 · Cited by 161
Liposomal amphotericin B as a treatment for human leishmaniasis
Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., Gaspani, S., Potet, J., & Chappuis, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.748036 · Cited by 160
Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients
Dorlo, T. P. C., van Thiel, P. P. A. M., Huitema, A. D. R., Keizer, R. J., de Vries, H. J. C., Beijnen, J. H., & de Vries, P. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00014-08 · Cited by 160
DENTON, H., McGregor, J. C., & Coombs, G. H. (2004) · Biochemical Journal · doi:10.1042/bj20040283 · Cited by 155
Prajapati, V. K., Awasthi, K., Gautam, S., Yadav, T. P., Rai, M., Srivastava, O. N., & Sundar, S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr002 · Cited by 154
Siqueira-Neto, J. L., Moon, S., Jang, J., Yang, G., Lee, C., Moon, H. K., Chatelain, E., Genovesio, A., Cechetto, J. D., & Freitas-Junior, L. H. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001671 · Cited by 153
Revisiting leishmaniasis in the time of war: the Syrian conflict and the Lebanese outbreak
Alawieh, A. M., Musharrafieh, U. M., Jaber, A., Berry, A., Ghosn, N., & Bizri, A. R. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.04.023 · Cited by 138
Bourreau, E., Ginouvès, M., Prévot, G., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv355 · Cited by 136
Adaui, V., Lye, L., Akopyants, N. S., Zimic, M., Llanos‐Cuentas, A., García, L., Maes, I., Doncker, S. D., Dobson, D. E., Arévalo, J., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv354 · Cited by 135
Pérez-Victoria, J. M., Pérez-Victoria, F. J., Parodi-Talice, A., Jiménez, I., Ravelo, Á., Castanys, S., & Gamarro, F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2468-2474.2001 · Cited by 135
HIV and the transmission ofLeishmania
Molina, R., Gradoni, L., & Alvar, J. (2003) · Annals of Tropical Medicine and Parasitology · doi:10.1179/000349803225002516 · Cited by 132
Seaman, J., Pryce, D. H., Sondorp, H. E., Moody, A. H., Bryceson, A. D. M., & Davidson, R. N. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.3.715 · Cited by 124
GRAMICCIA, M., Gradoni, L., & Orsini, S. (1992) · Annals of Tropical Medicine and Parasitology · doi:10.1080/00034983.1992.11812717 · Cited by 121
Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance.
Papadopoulou, B., Roy, G., Dey, S., Rosen, B. P., & Ouellette, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32670-4 · Cited by 120
Guimond, C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg806 · Cited by 118
Lachaud, L., Bourgeois, N., Plourde, M., Leprohon, P., Bastien, P., & Ouellette, M. (2008) · Clinical Infectious Diseases · doi:10.1086/595710 · Cited by 118
In VivoInterference of Paromomycin with Mitochondrial Activity ofLeishmania
Maarouf, M., de Kouchkovsky, Y., Brown, S., Petit, P. X., & Robert-Géro, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3500 · Cited by 113
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Manjunatha, U. H., & Smith, P. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.031 · Cited by 111
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
Kaiser, M., Mäser, P., Tadoori, L. P., Ioset, J., & Brun, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135556 · Cited by 111
Coelho, A. C., Boisvert, S., Mukherjee, A., Leprohon, P., Corbeil, J., & Ouellette, M. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001512 · Cited by 109
Self-citationde Moura, T. R., Novais, F. O., Oliveira, F., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.9.5827-5834.2005 · Cited by 108
Inhibitory activity of limonene against Leishmania parasites in vitro and in vivo
Arruda, D. C., Miguel, D. C., Yokoyama-Yasunaka, J. K. U., Katzin, A. M., & Uliana, S. R. B. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.02.004 · Cited by 105
Self-citationMiguel, D. C., Yokoyama-Yasunaka, J. K. U., Andreoli, W. K., Mortara, R. A., & Uliana, S. R. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm219 · Cited by 104
Self-citationManaging Resistance to Anti-HIV Drugs: An Important Consideration for Effective Disease Management
Vandamme, A., Laethem, K. V., & Clercq, E. D. (1999) · Drugs · doi:10.2165/00003495-199957030-00006 · Cited by 103
Kim, D. H., Chung, H. J., Bleys, J., & Ghohestani, R. F. (2009) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000381 · Cited by 100
Jirmanus, L. Z., Glesby, M. J., Guimarães, L. H., Lago, E., Rosa, M. E. A., Machado, P. R. L., & Carvalho, E. M. (2012) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.11-0378 · Cited by 100
Eco-epidemiology of visceral leishmaniasis in Ethiopia
Gadisa, E., Tsegaw, T., Abera, A., Elnaiem, D.-E. A., den Boer, M., Aseffa, A., & Jorge, A. (2015) · Parasites & Vectors · doi:10.1186/s13071-015-0987-y · Cited by 97
Bell, A., Mills, J. E. J., Williams, G. P., Brannigan, J. A., Wilkinson, A. J., Parkinson, T., Leatherbarrow, R. J., Tate, E. W., Holder, A. A., & Smith, D. F. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001625 · Cited by 95
do Monte‐Neto, R. L., Coelho, A. C., Raymond, F., Légaré, D., Corbeil, J., Melo, M. N., Frézard, F., & Ouellette, M. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001167 · Cited by 94
Self-citationAnnang, F. B., Pérez‐Moreno, G., García‐Hernández, R., Cordón-Obras, C., Martı́n, J., Tormo, J. R., Rodríguez, L., de Pedro, N., Gómez‐Pérez, V., Valente, M., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114555846 · Cited by 94
Díaz-González, R., Kuhlmann, F. M., Galan-Rodriguez, C., da Silva, L. M., Saldivia, M., Karver, C. E., Rodríguez, A., Beverley, S. M., Navarro, M., & Pollastri, M. P. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001297 · Cited by 92
Thakur, C. P., Olliaro, P., Gothoskar, S. V., Bhowmick, S., Choudhury, B., Prasad, S., Kumar, M., & Verma, B. B. (1992) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(92)90150-b · Cited by 92
A New ABC Half-Transporter in Leishmania major Is Involved in Resistance to Antimony
Manzano, J. I., García‐Hernández, R., Castanys, S., & Gamarro, F. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00211-13 · Cited by 91
Miguel, D. C., Zauli-Nascimento, R. C., Yokoyama-Yasunaka, J. K. U., Katz, S., Barbiéri, C. L., & Uliana, S. R. B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn509 · Cited by 90
Self-citationDifferential Effects of Paromomycin on Ribosomes ofLeishmania mexicanaand Mammalian Cells
Fernández, M. M., Malchiodi, E. L., & Algranati, I. D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00506-10 · Cited by 86
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Sn, J., Singh, N. K., & Tk, J. (1991) · PubMed · Cited by 85
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
Patterson, S., Wyllie, S., Norval, S., Stojanovski, L., Simeons, F. R. C., Auer, J. L., Osuna‐Cabello, M., Read, K. D., & Fairlamb, A. H. (2016) · eLife · doi:10.7554/elife.09744 · Cited by 85
do Monte‐Neto, R. L., Laffitte, M.-C. N., Leprohon, P., dos Reis, P. G., Frézard, F., & Ouellette, M. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003476 · Cited by 83
Leishmaniasis, conflict, and political terror: A spatio-temporal analysis
Berry, I., & Berrang‐Ford, L. (2016) · Social Science & Medicine · doi:10.1016/j.socscimed.2016.04.038 · Cited by 81
Michel, G., Ferruà, B., Lang, T., Maddugoda, M. P., Munro, P. M., Pomares-Estran, C., Lemichez, E., & Marty, P. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001323 · Cited by 79
Rai, K., Cuypers, B., Bhattarai, N. R., Uranw, S. K., Berg, M., Ostyn, B., Dujardin, J., Rijal, S., & Vanaerschot, M. (2013) · mBio · doi:10.1128/mbio.00611-13 · Cited by 78
Antileishmanial activity of nano-amphotericin B deoxycholate
Manandhar, K. D., Yadav, T. P., Prajapati, V. K., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn189 · Cited by 78
Shaw, C. D., Lonchamp, J., Downing, T., Imamura, H., Freeman, T. M., Cotton, J. A., Sanders, M. J., Blackburn, G. J., Dujardin, J., Rijal, S., et al. (2015) · Molecular Microbiology · doi:10.1111/mmi.13291 · Cited by 76
The leishmaniases. Report of a WHO Expert Committee.
(1984) · PubMed · Cited by 74
Comparison of regimens of treatment with sodium stibogluconate in kala-azar.
Thakur, C. P., Kumar, M., Singh, S. K., Sharma, D., Prasad, U., Singh, R. S., Dhawan, P. S., & Achari, V. (1984) · BMJ · doi:10.1136/bmj.288.6421.895 · Cited by 73
Improved Tricyclic Inhibitors of Trypanothione Reductase by Screening and Chemical Synthesis
Richardson, J. L., Nett, I., Jones, D. C., Abdille, M. H., Gilbert, I. H., & Fairlamb, A. H. (2009) · ChemMedChem · doi:10.1002/cmdc.200900097 · Cited by 71
Bhandari, V., Sundar, S., Dujardin, J., & Salotra, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01574-13 · Cited by 70
Coelho, A. C., Trinconi, C. T., Costa, C. H. N., & Uliana, S. R. B. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002999 · Cited by 69
Self-citationActivity of anti-cancer protein kinase inhibitors against Leishmania spp.
Sanderson, L., Yardley, V., & Croft, S. L. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku069 · Cited by 68
Mahajan, R., Das, P. K., Isaakidis, P., Sunyoto, T., Sagili, K. D., Lima, M. A., Mitra, G., Kumar, D., Pandey, K., Geertruyden, J. V., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ530 · Cited by 65
Li, C., Liu, B., Chang, J. J., Groessl, T., Zimmerman, M., He, Y.-Q., Isbell, J. J., & Tuntland, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.004 · Cited by 61
Kulshrestha, A., Sharma, V., Singh, R., & Salotra, P. (2014) · Parasitology Research · doi:10.1007/s00436-014-3755-6 · Cited by 54
Pandey, R. K., Sharma, D., Bhatt, T. K., Sundar, S., & Prajapati, V. K. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1085904 · Cited by 54
Cota, G., de Sousa, M. R., Fereguetti, T. O., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149697 · Cited by 51
In vitro Susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis
Prajapati, V. K., Sharma, S., Rai, M., Ostyn, B., Salotra, P., Vanaerschot, M., Dujardin, J., & Sundar, S. (2013) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.13-0096 · Cited by 49
Gene Amplification in Amphotericin B-Resistant Leishmania tarentolae
Singh, A. K., Papadopoulou, B., & Ouellette, M. (2001) · Experimental Parasitology · doi:10.1006/expr.2001.4663 · Cited by 44
HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals
van Griensven, J., Diro, E., López‐Vélez, R., Boelaert, M., Lynen, L., Zijlstra, E. E., Dujardin, J., & Hailu, A. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70348-1 · Cited by 44
Kumar, P., Lodge, R., Trudel, N., Ouellet, M., Ouellette, M., & Tremblay, M. J. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000642 · Cited by 43
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.
Valdivieso, E., Rangel, A., Moreno, J., Saugar, J. M., Cañavate, C., Alvar, J., & Dagger, F. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2010.06.002 · Cited by 42
Cellular models for ADMET predictions and evaluation of drug-drug interactions.
Rj, R., & Kenna, J. G. (2004) · PubMed · Cited by 38
Identification of the molecular attributes required for aminoglycoside activity against Leishmania
Shalev, M., Kondo, J., Kopelyanskiy, D., Jaffe, C. L., Adir, N., & Baasov, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307365110 · Cited by 37
Kulshrestha, A., Singh, R., Kumar, D., Negi, N. S., & Salotra, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00812-10 · Cited by 36
Purkait, B., Singh, R., Wasnik, K., Das, S., Kumar, A., Paine, M. J. I., Dikhit, M. R., Singh, D. P., Sardar, A. H., Ghosh, A. K., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku534 · Cited by 36
Gajdos, C., & Jordan, V. C. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.002 · Cited by 35
Discovery of high affinity inhibitors of Leishmania donovani N -myristoyltransferase
Rackham, M. D., Yu, Z., Brannigan, J. A., Heal, W. P., Paape, D., Barker, K. V., Wilkinson, A. J., Smith, D. F., Leatherbarrow, R. J., & Tate, E. W. (2015) · MedChemComm · doi:10.1039/c5md00241a · Cited by 33
Fortin, A., Hendrickx, S., Yardley, V., Cos, P., Jansen, H., & Maes, L. J. R. M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks273 · Cited by 32
Santos, D. M., Petersen, A. L. O. A., Celes, F. S., Borges, V. M., Veras, P. S. T., & de Oliveira, C. I. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003275 · Cited by 30
Gangwar, S., Baig, M. S., Shah, P., Biswas, S., Batra, S., Siddiqi, M. I., & Goyal, N. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01262.x · Cited by 18
Forestier, C.-L., Späth, G. F., Prina, E., & Dasari, S. (2014) · Microbial Pathogenesis · doi:10.1016/j.micpath.2014.10.012 · Cited by 17
Kauffmann, F., Dumetz, F., Hendrickx, S., Muraille, É., Dujardin, J., Maes, L. J. R. M., Magez, S., & Trez, C. D. (2016) · Parasite Immunology · doi:10.1111/pim.12316 · Cited by 3
Metadata
- Authors
- ULIANA, S. R. B., TRINCONI, C. T., & COELHO, A. C.
- Venue
- Parasitology
- Publisher
- Cambridge University Press (CUP)
- Published
- 2017-01-20
- Volume
- 145
- Issue
- 4
- Pages
- 464-480
- ISSN
- 0031-1820 (ISSN-L)
- 1469-8161
- OpenAlex
- W2573547936
- Cited by
- 261
- References
- 111
- FWCI
- 20.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.